The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates and are in various stages of clinical development
Drugmaker Merck will pay Daiichi Sankyo $5.5-billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22-billion to the Japanese firm depending on the success of the cell-targeting therapies.
The deal is a “big positive and much needed for Daiichi Sankyo,” said Tina Banerjee, a healthcare analyst who publishes on the Smartkarma platform. “This raises expectations from Daiichi’s oncology drug pipeline.” The drug candidates – patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan – have “multi-billion dollar worldwide commercial revenue potential for each company” by the mid-2030s, the two companies said.
Merck will pay Daiichi Sankyo $4-billion up front and $1.5-billion in continuation payments over the next two years. Merck may make additional payments of up to $16.5-billion, contingent on future sales milestones, or $5.5-billion for each product.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Merck signs $5.5 billion deal with Daiichi for cancer therapy developmentExplore stories from Atlantic Canada.
Lire la suite »
Merck KGaA says MS drug has blockbuster potential; key data expected in DecemberExplore stories from Atlantic Canada.
Lire la suite »
Merck KGaA raises prospect of return to sales growth next yearExplore stories from Atlantic Canada.
Lire la suite »
Merck KGaA says MS drug has blockbuster potential; key data expected in DecemberExplore stories from Atlantic Canada.
Lire la suite »